Egalet secured Shionogi as its first major partner in a deal focused on abuse-deterring forms of hydrocodone; to complement its specialty pharmacy portfolio, CVS acquired the infusion therapy business Coram for $2.1 billion. A $729 million debt offering by Incyte made up nearly one-third of the $2.5 billion in biopharma financing; and sources of public fundraising have been increasing over the past few months in the device industry, which raised $532 million.
Exhibit 1
Top Alliances In November 2013
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.